Clinical trials beginning for possible preeclampsia treatment

June 24, 2019

For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia - a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Now the researchers have published a study in the journal Scientific Reports that opens up opportunities for further research towards a drug they hope will save the lives of many pregnant women in the future.

The study was conducted in a transgenic mouse model of preeclampsia, the results are important since they confirm previous studies by the research team showing that alpha-1-microglobulin has potential therapeutic effects in preeclampsia. Trials on patients have recently been launched.

"The treatment, based on the human body's own scavenger protein A1M (alpha-1-microglobulin) which is present in all vertebrates, has a good effect on the disease symptoms such as high blood pressure and protein leakage from the kidneys into the urine. We also observed an improvement in organ function in the kidneys and the placenta. We saw no indication of side effects. In the study now published using the preeclampsia mouse model, which best reflects the various stages of the disease during pregnancy, the mice develop serious preeclampsia in early pregnancy", says Stefan Hansson, professor of obstetrics and gynaecology at Lund University and senior consultant physician at Skåne University Hospital in Lund, who is the principal investigator behind the study together with colleagues including senior researcher Lena Erlandsson.

"This feels like a milestone in our research, as patient studies, known as Phase 1 clinical trials, began in the spring to establish the properties of A1M in order to develop a drug."

Together with his colleague, Bo Åkerström, professor of infection medicine, Stefan Hansson started the studies on A1M several years ago and observed that A1M stopped the leakage of protein in the kidneys. They also saw that the placenta was repaired and that the destroyed structures in the cells' smallest components were restored.

"In preeclampsia, the cells of the placenta looked approximately as though all the trees had been blown over in a storm, and after treatment with A1M they stood up again. When I saw that for the first time, I became a scientific believer", explains Stefan Hansson.

The date for a potential drug to see the light of day is still uncertain.

"Research takes time and costs a lot of money. Bo Åkerström has spent his entire professional life on understanding and describing the properties of the A1M protein and, in the last ten years, we have been studying it in the laboratory as a drug candidate. The results from the clinical trials will be crucial", concludes Stefan Hansson.
-end-
The study in brief:

Subject: Obstetrics
Basic research, translational research
Study design: experimental study, animal study (STOX-1-mouse model for pre-eclampsia), in vivo.

Further information:

Stefan Hansson holds patents related to the diagnosis and treatment of preeclampsia and is the co-founder of A1M Pharma AB and Preelumina Diagnostics, as well as a shareholder. Lena Erlandsson and Erik Hedström are shareholders of A1M Pharma.

Lund University

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.